| Generic name | Brand name | Dose (mg/pill) | Maximum FDA-approved dosage (mg/d) | Duration of behavioral effects (hrs) |
|---|---|---|---|---|
| Methyphenidate | Ritalin | 5, 10, 20 | 60 | 2-4 |
| Methylphenidate SR | Ritalin SR, Metadate ER | 10, 20 | 60 | |
| ER methylphenidate | Ritalin LA | 10, 20, 30, 40 | 60 | 8-10 |
| Concerta | 18, 27, 36, 54 | 54 | 10-12 | |
| Metadate CD | 10, 20, 30 | 60 | 8-10 | |
| Dexmethyl-phenidate | Focalin | 2.5, 5, 10 | 20 | 3-6 |
| Dextro-amphetamine | Dexedrine, DextroStat | 5, 10 | 45 | 4-5 |
| Dextro-amphetamine SR | Dexedrine Spansules |
5, 10, 15 | 45 | |
| Amphetamine salts | Adderall | 5, 7.5, 10, 12.5, 15, 20, 30 | 45 | 5-7 |
| ER amphetamine salts | Adderall XR | 5, 10, 15, 20, 25, 30 | 30 | 8-10 |
| Pemoline | Cylert | 18.75, 37.5, 75 | 112.5 | 7-9 |
ER = extended release; FDA = U.S. Food and Drug Administration; SR = sustained release
Adapted from: Hirsch GS and Koplewicz HS. Attention-deficit hyperactivity disorder. In: Devinsky O and Westbrook LE, eds. Epilepsy and Developmental Disabilities. Boston: Butterworth-Heinemann; 2001;187-204.
With permission from Elsevier (www.elsevier.com).
Reviewed By:
Glenn S. Hirsch MD
on:
Tuesday, June 1, 2004
